|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0002871,
umls-concept:C0011945,
umls-concept:C0022661,
umls-concept:C0030705,
umls-concept:C0231449,
umls-concept:C0282460,
umls-concept:C0403447,
umls-concept:C0719517,
umls-concept:C1272706,
umls-concept:C1274040,
umls-concept:C1701991,
umls-concept:C2349182
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-6-4
|
|
pubmed:abstractText |
This study was designed to assess the potential of the continuous erythropoietin receptor activator (C.E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-na?ve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0301-0430
|
|
pubmed:author |
pubmed-author:BA 16528 Study Investigators,
pubmed-author:BesarabAA,
pubmed-author:Correa-RotterRR,
pubmed-author:DoughertyF CFC,
pubmed-author:EllisonD HDH,
pubmed-author:KlingerMM,
pubmed-author:MacdougallI CIC,
pubmed-author:MaxwellA PAP,
pubmed-author:ProvenzanoRR,
pubmed-author:RutkowskiBB,
pubmed-author:SulowiczWW
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
306-17
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17542340-Adult,
pubmed-meshheading:17542340-Aged,
pubmed-meshheading:17542340-Aged, 80 and over,
pubmed-meshheading:17542340-Analysis of Variance,
pubmed-meshheading:17542340-Anemia,
pubmed-meshheading:17542340-Area Under Curve,
pubmed-meshheading:17542340-Biological Markers,
pubmed-meshheading:17542340-Dose-Response Relationship, Drug,
pubmed-meshheading:17542340-Erythropoiesis,
pubmed-meshheading:17542340-Erythropoietin,
pubmed-meshheading:17542340-Female,
pubmed-meshheading:17542340-Ferritins,
pubmed-meshheading:17542340-Follow-Up Studies,
pubmed-meshheading:17542340-Hemoglobins,
pubmed-meshheading:17542340-Humans,
pubmed-meshheading:17542340-Kidney Failure, Chronic,
pubmed-meshheading:17542340-Male,
pubmed-meshheading:17542340-Middle Aged,
pubmed-meshheading:17542340-Polyethylene Glycols,
pubmed-meshheading:17542340-Recombinant Proteins,
pubmed-meshheading:17542340-Regression Analysis,
pubmed-meshheading:17542340-Renal Dialysis,
pubmed-meshheading:17542340-Time Factors,
pubmed-meshheading:17542340-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
|
|
pubmed:affiliation |
Division of Nephrology, St. John Hospital, 22201 Moross Road, Suite 150, Detroit, MI 48236, USA. robert.provenzano@stjohn.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
